Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement

被引:125
作者
Kanji, Salmaan [1 ,2 ]
Hayes, Meghan [3 ]
Ling, Adam [4 ]
Shamseer, Larissa [2 ,5 ]
Chant, Clarence [6 ,7 ]
Edwards, David J. [8 ]
Edwards, Scott [9 ]
Ensom, Mary H. H. [10 ,11 ]
Foster, David R. [12 ]
Hardy, Brian [7 ,13 ]
Kiser, Tyree H. [14 ]
la Porte, Charles [15 ]
Roberts, Jason A. [16 ,17 ,18 ]
Shulman, Rob [19 ]
Walker, Scott [13 ]
Zelenitsky, Sheryl [20 ]
Moher, David [2 ,21 ]
机构
[1] Ottawa Hosp, Dept Pharm, Ottawa, ON K1H 8L6, Canada
[2] Ottawa Hosp Res Inst, Ottawa, ON K1H 8L6, Canada
[3] Ottawa Hosp, Ottawa, ON K1H 8L6, Canada
[4] Univ Waterloo, Waterloo, ON N2L 3G1, Canada
[5] Univ Ottawa, Ottawa, ON, Canada
[6] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[7] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
[8] Univ Waterloo, Sch Pharm, Waterloo, ON N2L 3G1, Canada
[9] Mem Univ Newfoundland, Eastern Hlth, St John, NF, Canada
[10] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[11] Childrens & Womens Hlth Ctr British Columbia, Dept Pharm, Vancouver, BC, Canada
[12] Purdue Univ, Coll Pharm, W Lafayette, IN 47907 USA
[13] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[14] Univ Colorado, Dept Clin Pharm, Aurora, CO USA
[15] Janssen Cilag BV, Tilburg, Netherlands
[16] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia
[17] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
[18] Univ Liverpool, Inst Translat Med, Liverpool L69 3BX, Merseyside, England
[19] Univ Coll London Hosp NHS Trust, London, England
[20] Univ Manitoba, Coll Pharm, Winnipeg, MB, Canada
[21] Univ Ottawa, Fac Med, Ottawa, ON, Canada
基金
英国医学研究理事会;
关键词
CREATININE CLEARANCE; STRATEGIES; PREDICTION; MODELS;
D O I
10.1007/s40262-015-0236-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective Transparent reporting of all research is essential for assessing the validity of any study. Reporting guidelines are available and endorsed for many types of research but are lacking for clinical pharmacokinetic studies. Such tools promote the consistent reporting of a minimal set of information for end users, and facilitate knowledge translation of research. The objective of this study was to create a guideline to assist in the transparent and complete reporting of clinical pharmacokinetic studies. Methods Preliminary content to be considered was identified from a systematic search of the literature and regulatory documents. Stakeholders were identified to participate in a modified Delphi exercise and a virtual meeting to generate consensus for items considered essential in the reporting of clinical pharmacokinetic studies. The proposed checklist was pilot tested on 100 recently published clinical pharmacokinetic studies. Overall and ite mized compliance with the proposed guidance was determined for each study. Results Sixty-eight stakeholders from nine countries consented to participate. Four rounds of a modified Delphi survey and a series of small virtual meetings were required to generate consensus for a 24-item checklist considered to be essential to the reporting of clinical pharmacokinetic studies. When applied to the 100 most recently published clinical pharmacokinetic studies, 45 were determined to be compliant with at least 80 % of the checklist items. Explanatory text was prepared using examples of compliant reporting from these and other relevant studies. Conclusions The reader's ability to judge the validity of pharmacokinetic research can be greatly compromised by the incomplete reporting of study information. Using consensus methods, we have developed a tool to guide transparent and accurate reporting of clinical pharmacokinetic studies. Endorsement and implementation of these guidelines by researchers, clinicians and journals would promote more consistent reporting of these studies and allow for better assessment of utility for clinical applications.
引用
收藏
页码:783 / 795
页数:13
相关论文
共 25 条
  • [1] Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?
    Als-Nielsen, B
    Chen, WD
    Gluud, C
    Kjaergard, LL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07): : 921 - 928
  • [2] [Anonymous], 2010, CLIN PHARMACOKINETIC
  • [3] [Anonymous], 1999, Guidance for Industry: Population Pharmacokinetics (CP 1)
  • [4] [Anonymous], NOTE GUIDANCE EVALUA
  • [5] [Anonymous], CLINICAL PHARMACOKIN
  • [6] [Anonymous], 1998, Health Technol Assess
  • [7] [Anonymous], 2007, GUIDELINE REPORTING
  • [8] Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated?: A survey of the literature from 2002 to 2004
    Brendel, Karl
    Dartois, Celine
    Comets, Emmanuelle
    Lemenuel-Diot, Annabelle
    Laveille, Christian
    Tranchand, Brigitte
    Girard, Pascal
    Laffont, Celine M.
    Mentre, France
    [J]. CLINICAL PHARMACOKINETICS, 2007, 46 (03) : 221 - 234
  • [9] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [10] Overview of model-building strategies in population PK/PD analyses:: 2002-2004 literature survey
    Dartois, C.
    Brendel, K.
    Comets, E.
    Laffont, C. M.
    Laveille, C.
    Tranchand, B.
    Mentre, F.
    Lemenuel-Diot, A.
    Girard, P.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (05) : 603 - 612